Phathom Pharmaceuticals (PHAT) Competitors

$10.74 -0.36 (-3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$10.73 -0.01 (-0.09%)

As of 04:57 PM Eastern

PHAT vs. ORKA, ACAD, TLX, EWTX, and OGN

Should you buy Phathom Pharmaceuticals stock or one of its competitors? MarketBeat compares Phathom Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phathom Pharmaceuticals include Oruka Therapeutics (ORKA), ACADIA Pharmaceuticals (ACAD), Telix Pharmaceuticals (TLX), Edgewise Therapeutics (EWTX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.

How does Phathom Pharmaceuticals compare to Oruka Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Phathom Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.2, suggesting that its stock price is 120% less volatile than the broader market.

Oruka Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.89	-$221.25M	-$2.12	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 3 articles in the media. Oruka Therapeutics' average media sentiment score of 0.86 beat Phathom Pharmaceuticals' score of 0.15 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals currently has a consensus price target of $25.00, indicating a potential upside of 132.77%. Oruka Therapeutics has a consensus price target of $120.80, indicating a potential upside of 108.31%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Phathom Pharmaceuticals is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Oruka Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Summary

Phathom Pharmaceuticals beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to ACADIA Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Phathom Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.89	-$221.25M	-$2.12	N/A
ACADIA Pharmaceuticals	$1.07B	3.39	$391M	$2.20	9.63

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 3 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.15 beat ACADIA Pharmaceuticals' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phathom Pharmaceuticals currently has a consensus price target of $25.00, indicating a potential upside of 132.77%. ACADIA Pharmaceuticals has a consensus price target of $31.63, indicating a potential upside of 49.24%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Phathom Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Phathom Pharmaceuticals' net margin of -76.77%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Summary

ACADIA Pharmaceuticals beats Phathom Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Telix Pharmaceuticals has higher revenue and earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.11	-$7.12M	N/A	N/A
Phathom Pharmaceuticals	$175.11M	4.89	-$221.25M	-$2.12	N/A

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.34 beat Phathom Pharmaceuticals' score of 0.15 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Telix Pharmaceuticals presently has a consensus price target of $21.13, indicating a potential upside of 116.89%. Phathom Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 132.77%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Phathom Pharmaceuticals beats Telix Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Edgewise Therapeutics?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Phathom Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 132.77%. Edgewise Therapeutics has a consensus target price of $39.67, indicating a potential upside of 18.27%. Given Phathom Pharmaceuticals' higher possible upside, equities analysts plainly believe Phathom Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Phathom Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Edgewise Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.89	-$221.25M	-$2.12	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 3 mentions for Phathom Pharmaceuticals and 2 mentions for Edgewise Therapeutics. Phathom Pharmaceuticals' average media sentiment score of 0.15 beat Edgewise Therapeutics' score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Phathom Pharmaceuticals compare to Organon & Co.?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Organon & Co. has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.89	-$221.25M	-$2.12	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.38

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phathom Pharmaceuticals presently has a consensus target price of $25.00, suggesting a potential upside of 132.77%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 14.77%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.99% compared to Phathom Pharmaceuticals' net margin of -76.77%. Organon & Co.'s return on equity of 99.95% beat Phathom Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Organon & Co.	3.99%	99.95%	6.22%

In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 3 articles in the media. Organon & Co.'s average media sentiment score of 1.06 beat Phathom Pharmaceuticals' score of 0.15 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Organon & Co. beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Phathom Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAT vs. The Competition

Export

Metric	Phathom Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$885.29M	$3.38B	$6.41B	$12.49B
Dividend Yield	N/A	2.28%	2.75%	5.25%
P/E Ratio	-5.07	18.82	21.34	25.94
Price / Sales	4.89	339.20	548.85	90.76
Price / Cash	N/A	122.89	43.13	56.80
Price / Book	-2.55	7.16	10.40	7.14
Net Income	-$221.25M	$24.25M	$3.56B	$337.13M
7 Day Performance	-9.52%	4.54%	2.95%	3.36%
1 Month Performance	-7.33%	3.61%	2.40%	3.52%
1 Year Performance	160.68%	65.40%	36.13%	36.41%

Phathom Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAT Phathom Pharmaceuticals	2.7151 of 5 stars	$10.74 -3.2%	$25.00 +132.8%	+176.1%	$885.29M	$175.11M	N/A	110
ORKA Oruka Therapeutics	4.058 of 5 stars	$58.34 -5.8%	$120.80 +107.1%	+439.4%	$3.74B	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	4.0764 of 5 stars	$20.69 -3.3%	$31.18 +50.7%	-3.3%	$3.66B	$1.07B	9.40	510	Insider Trade
TLX Telix Pharmaceuticals	4.5464 of 5 stars	$10.28 -2.7%	$21.13 +105.5%	-42.3%	$3.58B	$803.79M	N/A	1,184
EWTX Edgewise Therapeutics	1.8425 of 5 stars	$31.72 -4.1%	$39.67 +25.1%	+136.2%	$3.56B	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAT) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. ORKA, ACAD, TLX, EWTX, and OGN

How does Phathom Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Phathom Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Phathom Pharmaceuticals compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phathom Pharmaceuticals (PHAT) Competitors

PHAT vs. ORKA, ACAD, TLX, EWTX, and OGN

How does Phathom Pharmaceuticals compare to Oruka Therapeutics?

Which has more volatility and risk, PHAT or ORKA?

Which has higher valuation and earnings, PHAT or ORKA?

Does the media favor PHAT or ORKA?

Do analysts rate PHAT or ORKA?

Do institutionals & insiders believe in PHAT or ORKA?

Is PHAT or ORKA more profitable?

Summary

How does Phathom Pharmaceuticals compare to ACADIA Pharmaceuticals?

Which has more volatility and risk, PHAT or ACAD?

Which has higher valuation and earnings, PHAT or ACAD?

Does the media favor PHAT or ACAD?

Do analysts rate PHAT or ACAD?

Do institutionals & insiders believe in PHAT or ACAD?

Is PHAT or ACAD more profitable?

Summary

How does Phathom Pharmaceuticals compare to Telix Pharmaceuticals?

Do insiders and institutionals believe in TLX or PHAT?

Which has better earnings & valuation, TLX or PHAT?

Does the media refer more to TLX or PHAT?

Which has more volatility and risk, TLX or PHAT?

Is TLX or PHAT more profitable?

Do analysts prefer TLX or PHAT?

Summary

How does Phathom Pharmaceuticals compare to Edgewise Therapeutics?

Do analysts rate PHAT or EWTX?

Which has more volatility and risk, PHAT or EWTX?

Is PHAT or EWTX more profitable?

Which has better valuation and earnings, PHAT or EWTX?

Does the media refer more to PHAT or EWTX?

Do insiders & institutionals believe in PHAT or EWTX?

Summary

How does Phathom Pharmaceuticals compare to Organon & Co.?

Which has better valuation and earnings, PHAT or OGN?

Do institutionals and insiders hold more shares of PHAT or OGN?

Do analysts recommend PHAT or OGN?

Is PHAT or OGN more profitable?

Does the media favor PHAT or OGN?

Which has more volatility & risk, PHAT or OGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT vs. The Competition

Phathom Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools